Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IMS Health Sees Global Pharma Growth At 4-6% In 2010
IMS Health estimates that the global pharmaceutical market in 2010 will grow 4-6% on a constant-dollar basis, exceeding $825 billion, driven by stronger near-term growth in the US
IMS Health estimates that the global pharmaceutical market in 2010 will grow 4-6% on a constant-dollar basis, exceeding $825 billion, driven by stronger near-term growth in the US
Arch Chemicals has entered into a trade accounts receivable securitisation facility with PNC Bank and its affiliate, Market Street Funding, which will provide up to $80m of funding
The FDA Antiviral Drugs Advisory Committee has recommended the approval of Pfizer’s Selzentry (maraviroc) tablets for use in treatment-naive adult patients with CCR5-tropic HIV-1 virus, as part of
GlaxoSmithKline (GSK) has reached an agreement with the US Patent and Trademark Office (USPTO) to join the latter’s motion to dismiss its litigation over Final Regulations published in
Medtronic has launched Captivia Delivery System for the Valiant Thoracic Stent Graft, a minimally invasive treatment for aneurysms and other lesions of the thoracic aorta. The system features
Edwards Lifesciences has revealed that it will be developing a new manufacturing facility in Draper, Utah, which will enable it to expand its manufacturing and R&D capability. The
Keryx Biopharmaceuticals (Keryx) has initiated phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small
Radient Pharmaceuticals, through its wholly-owned subsidiary, AMDL Diagnostics, has entered into an exclusive five-year marketing and distribution agreement with Grifols USA, a healthcare products manufacturer and distributor. Under
Lpath has reported positive results of its single-dose phase 1 clinical trial of isonep in wet-AMD patients. The result suggested that isonep met its primary endpoint of being
Sanofi Pasteur, the vaccines division of the sanofi-aventis group, has revealed that a single dose of influenza A (H1N1) 2009 monovalent vaccines, Panenza or Humenza, administered to children